Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Infusion of regulatory T cells is a promising therapeutic strategy in organ transplantation to modulate the immune system, prevent rejection, minimize the need for pharmaceutical immunosuppression, and improve long-term transplant outcomes. Here we describe a GMP-compliant method we have used for the manufacture of ex vivo expanded autologous regulatory T cells for use in clinical trials.

Original publication

DOI

10.1007/978-1-0716-2647-4_14

Type

Chapter

Publication Date

2023

Volume

2559

Pages

205 - 227

Keywords

Immunosuppression minimization, Regulatory T cells, Tolerance, Transplantation, Treg, Graft Rejection, Immune Tolerance, Immunosuppression Therapy, Organ Transplantation, Pharmaceutical Preparations, T-Lymphocytes, Regulatory